Contact Us
Belay Diagnostics CSF liquid biopsy for CNS malignancy diagnosis and monitoring

Summit 2.0 | Ascent | Vantage

Belay Summit™ 2.0 Comprehensive Genomic Profile

Tumor-derived nucleic acid in CSF

  • Next-generation sequencing
  • 520 genes (SNVs, MNVs, Indels)​
  • 62 CNVs​
  • 28 Fusions​
  • TMB and MSI

For chromosome arm-level loss/gain analysis, see our companion test, Belay AscentTM.

For our MGMT promoter methylation test, see Belay VantageTM

Why choose Belay Summit 2.0 Genomic Profile in CSF?​

Technical Bulletin
  • Molecular characterization can markedly enhance diagnostic accuracy, tumor classification, predictive prognosis, and treatment selection1​
  • CNS metastasis can have different molecular profiles than primary tumors with distinct targetable mutations, due to clonal evolution during neoplasm migration2​
  • Genomic abnormalities associated with CNS cancers can be detected prior to performing resections or biopsies that impose clinical risk
Summit 2.0 CSF genomic profiling clinical sensitivity 96% and specificity 98% across metastatic cancer and primary CNS malignancies including glioblastoma, oligodendroglioma, and medulloblastoma.
Summit 2.0 CSF genomic profiling analytical performance: 97% sensitivity and specificity for SNVs, MNVs, and indels; 100% sensitivity and specificity for CNVs and fusions; 100% sensitivity for TMB and MSI; limit of detection 0.3% VAF.

1. Park SH, Won J, Kim SI, Lee Y, Park CK, Kim SK, Choi SH. Molecular Testing of Brain Tumor. J Pathol Transl Med. 2017 May;51(3):205-223. doi: 10.4132/jptm.2017.03.08. Epub
2017 May 12. PMID: 28535583; PMCID: PMC5445205.
2. Shen E, Van Swearingen AED, Price MJ, Bulsara K, Verhaak RGW, Baëta C, Painter BD, Reitman ZJ, Salama AKS, Clarke JM, Anders CK, Fecci PE, Goodwin CR, Walsh KM. A Need for More Molecular Profiling in Brain Metastases. Front Oncol. 2022 Jan 25;11:785064. doi: 10.3389/fonc.2021.785064. PMID: 35145903; PMCID: PMC8821807.
3. Khurana S, Keo V, Larson A, Udhane V, Adams JN, Acevedo A, Peltier T, Sanchez D, Domagala BA, Vo SA, Mitchell K, Ellis D, Muhammedov B, Al-Saffar SI, Hernandez KM, Bettegowda C, Douville C, Schilter KF,  Nie Q, Reddi HV*. Analytical Validation and Clinical Sensitivity of the Belay  Summit™ 2.0 Cerebrospinal Fluid Liquid Biopsy Test—An Expanded Comprehensive Genomic Profiling Platform for Central Nervous System Malignancies.2026. Cancers. 18(2):256.

Let Us Help You Get Started

The future of genomic testing in CSF is here. Our team is ready to support you with test ordering, clinical questions, and patient resources.

Contact Us